Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population
Autore:
Someya, T; Suzuki, Y; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S;
Indirizzi:
Niigata Univ, Sch Med, Dept Psychiat, Niigata, Japan Niigata Univ Niigata Japan Univ, Sch Med, Dept Psychiat, Niigata, Japan Shiga Univ Med Sci, Dept Psychiat, Shiga, Japan Shiga Univ Med Sci ShigaJapan niv Med Sci, Dept Psychiat, Shiga, Japan Yoshitomi Pharmaceut Ind Ltd, Fukuoka, Japan Yoshitomi Pharmaceut Ind LtdFukuoka Japan ceut Ind Ltd, Fukuoka, Japan Saitama Kounan Hosp, Saitama, Japan Saitama Kounan Hosp Saitama JapanSaitama Kounan Hosp, Saitama, Japan
Titolo Testata:
PSYCHIATRY AND CLINICAL NEUROSCIENCES
fascicolo: 5, volume: 53, anno: 1999,
pagine: 593 - 597
SICI:
1323-1316(199910)53:5<593:TEOCP2>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEBRISOQUINE HYDROXYLATION PHENOTYPE; REDUCED HALOPERIDOL; POOR METABOLIZERS; CYP2D6; INVOLVEMENT; PLASMA; AMPLIFICATION; MONOOXYGENASE; DISPOSITION; OXIDATION;
Keywords:
cytochrome P450 (CYP) 2D6; genotype; haloperidol; plasma concentration; reduced haloperidol;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Someya, T Niigata Univ Med, Dept Psychiat, Niigata 9518510, Japan Niigata Univ Med Niigata Japan 9518510 Niigata 9518510, Japan
Citazione:
T. Someya et al., "The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population", PSY CLIN N, 53(5), 1999, pp. 593-597

Abstract

We investigated the effect of cytochrome P450 (CYP2D6) genotypes on plasmalevels of haloperidol (HAL) and reduced haloperidol (RHAL) in 47 Japanese male schizophrenic inpatients being treated with HAL. Mutation-specific polymerase chain reaction (PCR) analysis was used to detect CYP2D6*10 as the C188C1T mutation in exon 1. A long-PCR analysis method was used to detect CYP2D6*5, Allele frequencies of CYP2D6*5 and CYP2D6*10 were 4.3% and 34.0%, respectively. Plasma concentrations of HAL and RHAL were measured using high-performance liquid chromatography. The ranges of the plasma concentration of HAL and RHAL corrected to the dose were 0.28-1.60 (mean +/- SD, 0.66+/-0.25, n=47) ng/mL/mg and 0.03-3.00 (mean+/-SD, 0.36+/-0.46, n=47) ng/mL, respectively. Plasma RHAL/HAL ratios (R/H ratios) ranged from 0.06 to 1.85 (mean+/-SD, 0.48+/-0.32, n=47). The analysis was performed among the four genotype groups:CYP2D6*1/CYP206*1 (n=11), CYP2D6*1/CYP2D6*10 (n=11), CYP2D6*10/CYP2D6*10 (n=6) and those who have CYP2D6*5 allele (CYP2D6*1/ CYP2D6*5 or CYP2D6*5/CYP2D6*10 (n=4). We observed significant tendency in effects of CYP2D6 genotypes on plasma concentration of HAL and significant effects on plasma concentration of RHAL, and R/H ratio. These results we obtained suggested that the plasma concentration of HAL and RHAL were determined partly by CYP2D6 polymorphic activity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 21:55:42